Trevi Therapeutics’ (TRVI) “Buy” Rating Reiterated at D. Boral Capital

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a research report issued on Thursday,Benzinga reports. They currently have a $19.00 target price on the stock. D. Boral Capital’s price target would indicate a potential upside of 62.25% from the stock’s current price.

Several other brokerages also recently weighed in on TRVI. Morgan Stanley increased their price target on Trevi Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Friday, November 14th. Leerink Partners upped their price objective on Trevi Therapeutics from $13.00 to $16.00 and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Wednesday, October 8th. Oppenheimer raised their price target on shares of Trevi Therapeutics from $23.00 to $24.00 and gave the stock an “outperform” rating in a research note on Friday, November 14th. Finally, B. Riley upgraded shares of Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, November 17th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Trevi Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $21.10.

Trevi Therapeutics Trading Up 6.6%

Shares of TRVI opened at $11.71 on Thursday. The company’s fifty day simple moving average is $12.19 and its 200-day simple moving average is $9.45. The company has a market cap of $1.50 billion, a P/E ratio of -31.65 and a beta of 0.91. Trevi Therapeutics has a twelve month low of $3.47 and a twelve month high of $14.39.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.02. Analysts predict that Trevi Therapeutics will post -0.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Trevi Therapeutics

Several large investors have recently modified their holdings of TRVI. AQR Capital Management LLC lifted its position in shares of Trevi Therapeutics by 20.4% in the 1st quarter. AQR Capital Management LLC now owns 27,720 shares of the company’s stock worth $174,000 after purchasing an additional 4,688 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Trevi Therapeutics by 31.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,143 shares of the company’s stock worth $278,000 after buying an additional 10,445 shares in the last quarter. Millennium Management LLC lifted its holdings in Trevi Therapeutics by 356.3% during the first quarter. Millennium Management LLC now owns 823,249 shares of the company’s stock worth $5,178,000 after buying an additional 642,830 shares during the period. Fred Alger Management LLC bought a new stake in Trevi Therapeutics during the 1st quarter valued at $482,000. Finally, Strs Ohio bought a new stake in Trevi Therapeutics during the 1st quarter valued at $52,000. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.